Email this article 
Post a Comment 
Body mass index versus bladder and rectal doses using 2D planning for patients with carcinoma of the cervix undergoing HDR brachytherapy
Abstract
Purpose: To assess bladder and rectum doses in relation to body mass index of patients undergoing high dose rate brachytherapy for the treatment of carcinoma of the cervix.
Methods: The cohort consists of fifty subjects with carcinoma of the uterine cervix presented with grade II and III. Patient’s height and weight was measured before the insertion of applicator in situ. Body mass index (BMI) of the patient was calculated in accordance to World Health Organization definition (weight in Kg/ height in m2). Adequacy of position and orientation of the applicator was confirmed with the help of orthogonal X-ray images and the same were transferred to the treatment planning system (TPS) to generate treatment plan. Prescription doses were optimized to Point A and to reference lines placed at 0.5 cm apart from the surface of ovoids. The following dose reference points were identified on orthogonal x-ray images for analysis using the rectal marker and Foleys bulb inflated with radio opaque dye Rectal points at the level of femoral heads (RL) and pubis symphysis (RLP), Anorectum Junction (AR Jn) point and Rectosigmoid (RS) point and Bladder point (BL). Pearson regression analysis was used to analyze data from TPS.
Results: The mean BMI was 22.7 kg/m2 and average age was 49.9 years. Analysis showed that RL point dose and BMI were inversely correlated with a coefficient -0.45 (p = 0.001). The trend continued along the rectal tube in cranio-caudal direction, as RLP and AR Jn points showed inversion co-efficiency with increase in BMI,-0.48 (p < 0.01) and -0.51 (p < 0.01) respectively. Bladder point showed weak positive correlation to BMI, 0.12 (p = 0.38).
Conclusion: Significant rectal dose reduction is observed with increase in BMI. Bladder dose did not show statistically significant correlation with BMI. Based on the findings, BMI constitutes a confounding factor in the treatment of carcinoma of cervix.
Keywords
Full Text:
PDFReferences
Atahan IL, Onal C, Ozyar E, et al. Long-term outcome and prognostic factors in patients with cervical carcinoma: a retrospective study. Int J Gynecol Cancer. 2007;17(4):833-42.
Nag S, Cardenes H, Chang S, et al. Proposed guidelines for image-based intracavitary brachytherapy for cervical carcinoma: report from Image-Guided Brachytherapy Working Group. Int J Radiat Oncol Biol Phys. 2004; 60(4):1160-72.
Nag S. High dose rate brachytherapy: its clinical applications and treatment guidelines. Technol Cancer Res Treat. 2004;3(3):269-87.
Viani GA, Manta GB, Stefano EJ, et al. Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy -a meta- analysis of clinical trials. J Exp Clin Cancer Res. 2009;28-47.
Moyad MA. Is obesity a risk factor for prostate cancer, and dose it even matter? A hypothesis and different perspective. Urology 2002; 59:41-50.
Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med. 1999;341:427-34.
Lukanova A, Lundin E, Zeleniuch-Jacquotte A, et al. Body mass index. Circulating levels of sex-steroid hormones. IGF-I and IGF- binding protein-3: A cross-sectional study in healthy women. Eur J Endocrinol. 2004;150:161-71.
Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95:1218-26.
Nag S, Erickson B, Thomadsen B, et al. The American brachytherapy society recommendations for High Dose Rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phy. 2000;48:201-11.
Georg P, Lang S, Dimopoulos JC, et al. Dose-volume histogram parameters and late side effects in magnetic resonance image guided adaptive cervical cancer Brachytherapy. Int J Radiat Oncol Biol Phy. 2011;79:356-62.
Huang EY, Wang CJ, Hsu HC, et al. Dosimetric factors predicting severe radiation- induced bowel complication in patients with cervical cancer: Combined effect of external parametrial dose and cumulative rectal dose. Gynecol Oncol. 2004;95:101-8.
Stryker JA, Bartholomew M, Velkly DE, et al. Bladder and rectal complications following radiotherapy for cervix cancer. Gynecol Oncol. 1988;29:1-11.
Nora TK, Premal HT, Feng Gao, et al. The effects of body mass index on complications and surivival out comes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011;117:948-56.
Jihoon L, Blythe DJ, Richard V, et al. The impact of body mass index on rectal dose in locally advanced cervical cancer treated with high dose rate Brachytherapy. Brachytherapy. 2013; 12:550-4.
Barbosa NA, da Rosa LAR, de Menezes AF, et al. Assessment of ocular beta radiation dose distribution due to 106Ru/106Rh brachytherapy applicators using MCNPX Monte Carlo code. Int J Cancer Ther Oncol. 2014; 2(3):02038.
Muralidhar KR, Rout BK, Mallikarjuna A, et al. Commissioning and quality assurances of the Intrabeam Intra-Operative radiotherapy unit. Int J Cancer Ther Oncol. 2014;2(4):020415.
Kizer NT, Thaker PH, Gao F, et al. The effects of body mass index on complications and survival outcome in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011;117:948-56.
Boyle JM, Craciunescu O, Steffey B, et al. Body mass index, dose to organs at risk during vaginal brachytherapy, and the role of three-dimensional CT-based treatment planning. Brachytherapy. 2014;13:332-6.
DOI: http://dx.doi.org/10.14319/ijcto.42.2
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.
Number of visits since October, 2013